1.
2.
3.
4.
5.
442
Sepanlou SG, Safiri S, Bisignano C, et al. The global, regional,
and national burden of cirrhosis by cause in 195 countries and
territories, 1990-2017: a systematic analysis for the Global
Burden of Disease Study 2017. Lancet Gastroenterol Hepatol
2020; 5:245–266.
Byrne CD, Targher G. NAFLD: a multisystem disease. J
Hepatol 2015; 62(Suppl):S47–S64.
Gluchowski NL, Becuwe M, Walther TC, Farese RV Jr. Lipid
droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol 2017; 14:343–355.
Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis
and prevention of hepatic steatosis. Gastroenterol Hepatol
(N Y) 2015; 11:167–175.
Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C.
Epidemiological and etiological variations in hepatocellular
carcinoma. Infection 2020; 48:7–17.
6. Tanaka J, Akita T, Ko K, Miura Y, Satake M. Countermeasures
against viral hepatitis B and C in Japan: An epidemiological
point of view. Hepatol Res 2019; 49:990–1002.
7. Wong SW, Ting YW, Chan WK. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and
its implications. JGH Open. 2018; 2:235–241.
8. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on
nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019; 69:2672–2682.
9. Calzadilla Bertot L, Adams LA. The natural course of nonalcoholic fatty liver disease. Int J Mol Sci 2016; 17:774.
10. McPherson S, Hardy T, Henderson E, Burt AD, Day CP,
Anstee QM. Evidence of NAFLD progression from steatosis
to fibrosing-steatohepatitis using paired biopsies: implications
for prognosis and clinical management. J Hepatol 2015;
62:1148–1155.
11. Pais R, Charlotte F, Fedchuk L, et al. A systematic review of
follow-up biopsies reveals disease progression in patients with
non-alcoholic fatty liver. J Hepatol 2013; 59:550–556.
12. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba
R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of
paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;
13:643–654.e1–9; quiz e39–40.
13. Wong VW, Wong GL, Choi PC, et al. Disease progression of
non-alcoholic fatty liver disease: a prospective study with
paired liver biopsies at 3 years. Gut 2010; 59:969–974.
14. Angulo P, Hui JM, Marchesini G, et al. The NAFLD
fibrosis score: a noninvasive system that identifies liver
fibrosis in patients with NAFLD. Hepatology 2007;
45:846–854.
15. Balakrishnan M, Loomba R. The role of noninvasive tests for
differentiating NASH from NAFL and diagnosing advanced
fibrosis among patients with NAFLD. J Clin Gastroenterol
2020; 54:107–113.
16. Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018; 68:349–
360.
17. Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions
and pathogenesis. J Gastroenterol Hepatol 2002; 17(Suppl 3):
S377–S384.
18. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty
liver disease. Hepatology 2005; 41:1313–1321.
19. Boyd A, Cain O, Chauhan A, Webb GJ. Medical liver biopsy:
background, indications, procedure and histopathology.
Frontline Gastroenterol 2020; 11:40–47.
20. Jayakumar S, Middleton MS, Lawitz EJ, et al. Longitudinal
correlations between MRE, MRI-PDFF, and liver histology in
patients with non-alcoholic steatohepatitis: Analysis of data
from a phase II trial of selonsertib. J Hepatol 2019; 70:133–
141.
21. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of
liver biopsy in nonalcoholic fatty liver disease.
Gastroenterology 2005; 128:1898–1906.
22. Tapper EB, Lok ASF. Use of liver imaging and biopsy in
clinical practice. N Engl J Med 2017; 377:756–768.
Magnetic Resonance in Medical Sciences
Quantitative MRI of Liver
23. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili
R, Ruggiero G. Steatosis accelerates the progression of liver
damage of chronic hepatitis C patients and correlates with
specific HCV genotype and visceral obesity. Hepatology 2001;
33:1358–1364.
24. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and
management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver
Diseases. Hepatology 2018; 67:328–357.
25. Rui L. Energy metabolism in the liver. Compr Physiol 2014;
4:177–197.
26. Fischer MA, Nanz D, Reiner CS, et al. Diagnostic performance
and accuracy of 3-D spoiled gradient-dual-echo MRI with
water- and fat-signal separation in liver-fat quantification:
comparison to liver biopsy. Invest Radiol 2010; 45:465–470.
27. Hayashi T, Saitoh S, Takahashi J, et al. Hepatic fat quantification using the two-point Dixon method and fat color maps
based on non-alcoholic fatty liver disease activity score.
Hepatol Res 2017; 47:455–464.
28. Hamilton G, Yokoo T, Bydder M, et al. In vivo characterization
of the liver fat 1H MR spectrum. NMR Biomed 2011; 24:784–
790.
29. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative
assessment of liver fat with magnetic resonance imaging and
spectroscopy. J Magn Reson Imaging 2011; 34:729–749.
30. Lee SS, Lee Y, Kim N, et al. Hepatic fat quantification using
chemical shift MR imaging and MR spectroscopy in the presence of hepatic iron deposition: validation in phantoms and
in patients with chronic liver disease. J Magn Reson Imaging
2011; 33:1390–1398.
31. Meisamy S, Hines CD, Hamilton G, et al. Quantification of
hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with
MR spectroscopy. Radiology 2011; 258:767–775.
32. Hernando D, Sharma SD, Kramer H, Reeder SB. On the
confounding effect of temperature on chemical shift-encoded
fat quantification. Magn Reson Med 2014; 72:464–470.
33. Reeder SB, Robson PM, Yu H, et al. Quantification of hepatic
steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 2009; 29:1332–1339.
34. Tang A, Desai A, Hamilton G, et al. Accuracy of MR
imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 2015; 274:416–425.
35. Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease:
MR imaging of liver proton density fat fraction to assess
hepatic steatosis. Radiology 2013; 267:422–431.
36. Qu Y, Li M, Hamilton G, Zhang YN, Song B. Diagnostic
accuracy of hepatic proton density fat fraction measured by
magnetic resonance imaging for the evaluation of liver steatosis with histology as reference standard: a meta-analysis. Eur
Radiol 2019; 29:5180–5189.
37. Yokoo T, Serai SD, Pirasteh A, et al. Linearity, bias, and
precision of hepatic proton density fat fraction measurements
by using MR imaging: A meta-analysis. Radiology 2018;
286:486–498.
38. Bannas P, Kramer H, Hernando D, et al. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex
vivo human livers. Hepatology 2015; 62:1444–1455.
Vol. 22, No. 4
39. Sofue K, Mileto A, Dale BM, Zhong X, Bashir MR.
Interexamination repeatability and spatial heterogeneity of
liver iron and fat quantification using MRI-based multistep
adaptive fitting algorithm. J Magn Reson Imaging 2015;
42:1281–1290.
40. Labranche R, Gilbert G, Cerny M, et al. Liver iron quantification with MR imaging: A primer for radiologists.
Radiographics 2018; 38:392–412.
41. Wood JC. Guidelines for quantifying iron overload.
Hematology (Am Soc Hematol Educ Program) 2014;
2014:210–215.
42. Anderson ER, Shah YM. Iron homeostasis in the liver. Compr
Physiol 2013; 3:315–330.
43. Corradini E, Pietrangelo A. Iron and steatohepatitis. J
Gastroenterol Hepatol 2012; 27(Suppl2): 42–46.
44. Milic S, Mikolasevic I, Orlic L, et al. The role of iron and iron
overload in chronic liver disease. Med Sci Monit 2016;
22:2144–2151.
45. Bashir MR, Wolfson T, Gamst AC, et al. Hepatic R2* is more
strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty
liver disease. J Magn Reson Imaging 2019; 49:1456–1466.
46. Armstrong T, Dregely I, Stemmer A, et al. Free-breathing liver
fat quantification using a multiecho 3D stack-of-radial technique. Magn Reson Med 2018; 79:370–382.
47. Armstrong T, Ly KV, Murthy S, et al. Free-breathing quantification of hepatic fat in healthy children and children with
nonalcoholic fatty liver disease using a multi-echo 3-D stackof-radial MRI technique. Pediatr Radiol 2018; 48:941–953.
48. Lohöfer FK, Kaissis GA, Müller-Leisse C, et al. Acceleration of
chemical shift encoding-based water fat MRI for liver proton
density fat fraction and T2* mapping using compressed sensing. PLoS One 2019; 14:e0224988.
49. Mann LW, Higgins DM, Peters CN, et al. Accelerating MR
imaging liver steatosis measurement using combined compressed sensing and parallel imaging: A quantitative evaluation. Radiology 2016; 278:247–256.
50. Lustig M, Donoho D, Pauly JM. Sparse MRI The application
of compressed sensing for rapid MR imaging. Magn Reson
Med 2007; 58:1182–1195.
51. Chappell KE, Patel N, Gatehouse PD, et al. Magnetic resonance imaging of the liver with ultrashort TE (UTE) pulse
sequences. J Magn Reson Imaging 2003; 18:709–713.
52. Zhu A, Hernando D, Johnson KM, Reeder SB. Characterizing
a short T2* signal component in the liver using ultrashort TE
chemical shift-encoded MRI at 1.5T and 3.0T. Magn Reson
Med 2019; 82:2032–2045.
53. Horng DE, Hernando D, Reeder SB. Quantification of liver fat
in the presence of iron overload. J Magn Reson Imaging 2017;
45:428–439.
54. Liau J, Shiehmorteza M, Girard OM, Sirlin CB, Bydder M.
Evaluation of MRI fat fraction in the liver and spine pre and
post SPIO infusion. Magn Reson Imaging 2013; 31:1012–1016.
55. Bashir MR, Zhong X, Nickel MD, et al. Quantification of
hepatic steatosis with a multistep adaptive fitting MRI
approach: prospective validation against MR spectroscopy.
AJR Am J Roentgenol 2015; 204:297–306.
56. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance
imaging more accurately classifies steatosis and fibrosis in
443
Y. Tsujita et al.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
444
patients with nonalcoholic fatty liver disease than transient
elastography. Gastroenterology 2016; 150:626–637.e7.
Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance
elastography vs transient elastography in detection of fibrosis
and noninvasive measurement of steatosis in patients with
biopsy-proven
nonalcoholic
fatty
liver
disease.
Gastroenterology 2017; 152:598–607.e2.
Raptopoulos V, Karellas A, Bernstein J, Reale FR,
Constantinou C, Zawacki JK. Value of dual-energy CT in
differentiating focal fatty infiltration of the liver from lowdensity masses. AJR Am J Roentgenol 1991; 157:721–725.
Hyodo T, Yada N, Hori M, et al. Multimaterial decomposition
algorithm for the quantification of liver fat content by using
fast-kilovolt-peak switching dual-energy CT: Clinical
Evaluation. Radiology 2017; 283:108–118.
Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 2020; 9:875.
Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but
no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.
Gastroenterology 2015; 149:389–397.e10.
Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the
strongest predictor for disease-specific mortality in NAFLD
after up to 33 years of follow-up. Hepatology 2015; 61:1547–
1554.
Muthupillai R, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca
A, Ehman RL. Magnetic resonance elastography by direct
visualization of propagating acoustic strain waves. Science
1995; 269:1854–1857.
Rouvière O, Yin M, Dresner MA, et al. MR elastography of the
liver: preliminary results. Radiology 2006; 240:440–448.
Overmoyer BA, McLaren CE, Brittenham GM. Uniformity of
liver density and nonheme (storage) iron distribution. Arch
Pathol Lab Med 1987; 111:549–554.
Cui J, Heba E, Hernandez C, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the
Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study. Hepatology 2016;
63:453–461.
Singh S, Venkatesh SK, Loomba R, et al. Magnetic resonance
elastography for staging liver fibrosis in non-alcoholic fatty
liver disease: a diagnostic accuracy systematic review and
individual participant data pooled analysis. Eur Radiol 2016;
26:1431–1440.
Ichikawa S, Motosugi U, Ichikawa T, et al. Magnetic resonance
elastography for staging liver fibrosis in chronic hepatitis C.
Magn Reson Med Sci 2012; 11:291–297.
Masugi Y, Abe T, Tsujikawa H, et al. Quantitative assessment of
liver fibrosis reveals a nonlinear association with fibrosis stage in
nonalcoholic fatty liver disease. Hepatol Commun 2018; 2:58–68.
Venkatesh SK, Wang G, Lim SG, Wee A. Magnetic resonance
elastography for the detection and staging of liver fibrosis in
chronic hepatitis B. Eur Radiol 2014; 24:70–78.
Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance
of magnetic resonance elastography in staging liver fibrosis: a
systematic review and meta-analysis of individual participant
data. Clin Gastroenterol Hepatol 2015; 13:440–451.e6.
Radiological Society of North America. QIBA Profile: Magnetic
Resonance Elastography of the Liver. Stage 2: consensus profile.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
https://qibawiki.rsna.org/images/a/a5/MRE-QIBAProfile-201805-02-CONSENSUS.pdf. (Accessed: Feb 15, 2022)
Lee DH, Lee JM, Han JK, Choi BI. MR elastography of healthy
liver parenchyma: Normal value and reliability of the liver
stiffness value measurement. J Magn Reson Imaging 2013;
38:1215–1223.
Motosugi U, Ichikawa T, Amemiya F, et al. Cross-validation of MR elastography and ultrasound transient elastography in liver stiffness measurement: discrepancy in the
results of cirrhotic liver. J Magn Reson Imaging 2012;
35:607–610.
Yoon JH, Lee JM, Joo I, et al. Hepatic fibrosis: prospective
comparison of MR elastography and US shear-wave elastography for evaluation. Radiology 2014; 273:772–782.
Toguchi M, Tsurusaki M, Yada N, et al. Magnetic resonance
elastography in the assessment of hepatic fibrosis: a study
comparing transient elastography and histological data in
the same patients. Abdom Radiol (NY) 2017; 42:1659–1666.
Morisaka H, Motosugi U, Glaser KJ, et al. Comparison of
diagnostic accuracies of two- and three-dimensional MR elastography of the liver. J Magn Reson Imaging 2017; 45:1163–
1170.
Loomba R, Cui J, Wolfson T, et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced
fibrosis in NAFLD: A prospective study. Am J Gastroenterol
2016; 111:986–994.
Kim DW, Kim SY, Yoon HM, Kim KW, Byun JH.
Comparison of technical failure of MR elastography for
measuring liver stiffness between gradient-recalled
echo and spin-echo echo-planar imaging: A systematic
review and meta-analysis. J Magn Reson Imaging 2020;
51:1086–1102.
Choi SL, Lee ES, Ko A, et al. Technical success rates and
reliability of spin-echo echo-planar imaging (SE-EPI) MR
elastography in patients with chronic liver disease or liver
cirrhosis. Eur Radiol 2020; 30:1730–1737.
Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs
transient elastography analysis of patients with nonalcoholic
fatty liver disease: A systematic review and pooled analysis of
individual participants. Clin Gastroenterol Hepatol 2019;
17:630–637.e8.
Yoon JH, Lee JM, Woo HS, et al. Staging of hepatic fibrosis:
comparison of magnetic resonance elastography and shear
wave elastography in the same individuals. Korean J Radiol
2013; 14:202–212.
Shire NJ, Yin M, Chen J, et al. Test-retest repeatability of MR
elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging 2011; 34:947–955.
Trout AT, Serai S, Mahley AD, et al. Liver stiffness measurements with MR elastography: Agreement and repeatability
across imaging systems, field strengths, and pulse sequences.
Radiology 2016; 281:793–804.
Taouli B, Tolia AJ, Losada M, et al. Diffusion-weighted MRI
for quantification of liver fibrosis: preliminary experience.
AJR Am J Roentgenol 2007; 189:799–806.
Wang Y, Ganger DR, Levitsky J, et al. Assessment of chronic
hepatitis and fibrosis: comparison of MR elastography and
diffusion-weighted imaging. AJR Am J Roentgenol 2011;
196:553–561.
Magnetic Resonance in Medical Sciences
Quantitative MRI of Liver
87. Jang W, Jo S, Song JS, Hwang HP, Kim SH. Comparison of
diffusion-weighted imaging and MR elastography in staging
liver fibrosis: a meta-analysis. Abdom Radiol (NY) 2021;
46:3889–3907.
88. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E,
Laval-Jeantet M. MR imaging of intravoxel incoherent
motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161:401–407.
89. Fu F, Li X, Chen C, et al. Non-invasive assessment of hepatic
fibrosis: comparison of MR elastography to transient elastography and intravoxel incoherent motion diffusionweighted MRI. Abdom Radiol (NY) 2020; 45:73–82.
90. Ichikawa S, Motosugi U, Morisaka H, et al. MRI-based staging
of hepatic fibrosis: Comparison of intravoxel incoherent
motion diffusion-weighted imaging with magnetic resonance
elastography. J Magn Reson Imaging 2015; 42:204–210.
91. Kromrey ML, Le Bihan D, Ichikawa S, Motosugi U.
Diffusion-weighted MRI-based virtual elastography for
the assessment of liver fibrosis. Radiology 2020;
295:127–135.
92. Le Bihan D, Ichikawa S, Motosugi U. Diffusion and intravoxel incoherent motion MR imaging-based virtual elastography: A hypothesis-generating study in the liver.
Radiology 2017; 285:609–619.
93. Obmann VC, Berzigotti A, Catucci D, et al. T1 mapping of
the liver and the spleen in patients with liver fibrosis-does
normalization to the blood pool increase the predictive
value? Eur Radiol 2021; 31:4308–4318.
94. Suyama Y, Tomita K, Soga S, et al. T1 magnetic resonance imaging value as a potential marker to assess the
severity of liver fibrosis: A pilot study. Eur J Radiol
Open 2021; 8:100321.
95. Day CP, James OF. Steatohepatitis: a tale of two “hits”?
Gastroenterology 1998; 114:842–845.
96. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52:1836–1846.
97. Li X, Wang H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell Biosci
2020; 10:140.
98. Shi Y, Guo Q, Xia F, et al. MR elastography for the
assessment of hepatic fibrosis in patients with chronic
hepatitis B infection: does histologic necroinflammation
influence the measurement of hepatic stiffness?
Radiology 2014; 273:88–98.
99. Ichikawa S, Motosugi U, Nakazawa T, et al. Hepatitis activity
should be considered a confounder of liver stiffness measured with MR elastography. J Magn Reson Imaging 2015;
41:1203–1208.
Vol. 22, No. 4
100. Asbach P, Klatt D, Hamhaber U, et al. Assessment of liver
viscoelasticity using multifrequency MR elastography. Magn
Reson Med 2008; 60:373–379.
101. Deffieux T, Montaldo G, Tanter M, Fink M. Shear wave
spectroscopy for in vivo quantification of human soft tissues
visco-elasticity. IEEE Trans Med Imaging 2009; 28:313–322.
102. Kruse SA, Smith JA, Lawrence AJ, et al. Tissue characterization using magnetic resonance elastography: preliminary
results. Phys Med Biol 2000; 45:1579–1590.
103. Yin M, Glaser KJ, Manduca A, et al. Distinguishing between
hepatic inflammation and fibrosis with MR elastography.
Radiology 2017; 284:694–705.
104. Sofue K, Onoda M, Tsurusaki M, et al. Dual-frequency MR
elastography to differentiate between inflammation and
fibrosis of the liver: Comparison with histopathology. J
Magn Reson Imaging 2020; 51:1053–1064.
105. Shi Y, Qi YF, Lan GY, et al. Three-dimensional MR elastography depicts liver inflammation, fibrosis, and portal
hypertension in chronic hepatitis B or C. Radiology 2021;
301:154–162.
106. Fujimoto K, Tonan T, Azuma S, et al. Evaluation of the mean
and entropy of apparent diffusion coefficient values in chronic
hepatitis C: correlation with pathologic fibrosis stage and inflammatory activity grade. Radiology 2011; 258:739–748.
107. Taouli B, Chouli M, Martin AJ, Qayyum A, Coakley FV,
Vilgrain V. Chronic hepatitis: role of diffusion-weighted
imaging and diffusion tensor imaging for the diagnosis of
liver fibrosis and inflammation. J Magn Reson Imaging
2008; 28:89–95.
108. França M, Martí-Bonmatí L, Alberich-Bayarri Á, et al.
Evaluation of fibrosis and inflammation in diffuse liver diseases using intravoxel incoherent motion diffusion-weighted
MR imaging. Abdom Radiol (NY) 2017; 42:468–477.
109. Tosun M, Onal T, Uslu H, Alparslan B, Çetin Akhan S.
Intravoxel incoherent motion imaging for diagnosing and
staging the liver fibrosis and inflammation. Abdom Radiol
(NY) 2020; 45:15–23.
110. Hoad CL, Palaniyappan N, Kaye P, et al. A study of T1
relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. NMR Biomed
2015; 28:706–714.
111. Hueper K, Lang H, Hartleben B, et al. Assessment of liver
ischemia reperfusion injury in mice using hepatic T2 mapping: Comparison with histopathology. J Magn Reson
Imaging 2018; 48:1586–1594.
112. Song J, Yu X, Song W, et al. MRI-based radiomics models
developed with features of the whole liver and right liver lobe:
Assessment of hepatic inflammatory activity in chronic hepatic
disease. J Magn Reson Imaging 2020; 52:1668–1678.
445
...
論文の公開元へ
